The Italian Multiple Sclerosis Foundation (FISM) is funding STOP-MS, an innovative research project aimed at developing a new therapeutic approach for multiple sclerosis (MS).

Among the key players in the project is ChemiCare, an innovative SME incubated and supported by Bio4Dreams, specializing in the development of drugs that modulate Store-Operated Calcium Entry (SOCE), a key mechanism in immune cell function.

In addition to STOP-MS, ChemiCare is already actively researching other diseases with its molecule CIC-39, which has received orphan drug designation from both the FDA and EMA for Duchenne muscular dystrophy.

STOP-MS: developing a new drug for MS

The STOP-MS project is a one-year pilot study aimed at developing a novel therapeutic approach for multiple sclerosis.

The initiative brings together ChemiCare, the Multiple Sclerosis Center of the “Maggiore della Carità” University Hospital, and the Immunomics Laboratory of the Department of Health Sciences at the University of Eastern Piedmont (UPO).

The focus of the research is to evaluate the potential of CIC-39, a negative modulator of SOCE, as a new therapeutic strategy for MS. This innovative approach could pave the way for new treatment prospects for patients affected by this disease.

Il focus della ricerca è valutare il potenziale di CIC-39, modulatore negativo di SOCE, come nuova strategia terapeutica nel trattamento della SM. Tale approccio innovativo potrà aprire la strada a nuove prospettive per i pazienti affetti da questa malattia.

📗 Learn more about ChemiCare and other companies in our portfolio.